Research and reference on the classification management system of prescription drugs and non-prescription drugs in Canada

XU Gan; LUO Weihua; SONG Haibo

doi:10.6039/j.issn.1001-0408.2023.01.01

您当前的位置：

首页 >

文章列表页 >

Research and reference on the classification management system of prescription drugs and non-prescription drugs in Canada

更新时间：2025-09-26

- Research and reference on the classification management system of prescription drugs and non-prescription drugs in Canada
- ZHONGGUO YAOFANG Vol. 34, Issue 1, Pages: 1-6(2023)
- 作者机构：
  
  1.北京中医药大学管理学院，北京　102488
  2.国家药品监督管理局药品评价中心，北京　100022
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.01.01
  CLC： R951
- Received：20 July 2022，
  
  Revised：2022-10-31，
  
  Published：15 January 2023
- 稿件说明：
移动端阅览
徐敢,罗卫花,宋海波.加拿大处方药与非处方药分类管理制度研究与借鉴[J].中国药房,2023,34(01):1-6.

XU Gan,LUO Weihua,SONG Haibo.Research and reference on the classification management system of prescription drugs and non-prescription drugs in Canada[J].ZHONGGUO YAOFANG,2023,34(01):1-6.
徐敢,罗卫花,宋海波.加拿大处方药与非处方药分类管理制度研究与借鉴[J].中国药房,2023,34(01):1-6. DOI： 10.6039/j.issn.1001-0408.2023.01.01.

XU Gan,LUO Weihua,SONG Haibo.Research and reference on the classification management system of prescription drugs and non-prescription drugs in Canada[J].ZHONGGUO YAOFANG,2023,34(01):1-6. DOI： 10.6039/j.issn.1001-0408.2023.01.01.

摘要

目的

借鉴加拿大处方药与非处方药分类管理制度，为完善我国处方药与非处方药分类管理提供借鉴。

方法

通过分析加拿大处方药与非处方药分类管理制度内容和经验，提出完善我国处方药与非处方药分类管理的思路。

结果与结论

按照处方药与非处方药分类，加拿大将药品分为第Ⅰ类药品、第Ⅱ类药品、第Ⅲ类药品和未分类药品，并对药品分类确立了具体评价因素和管理要求，建有一套比较系统的管理制度、体系和技术标准，这对完善我国处方药与非处方药分类管理制度具有参考和借鉴价值。笔者建议借鉴加拿大处方药和非处方药制度和管理模式，进一步完善我国药品分类管理制度和配套政策，加强处方药和非处方药的精细化分类管理，完善分类注册和转换审查标准。

Abstract

OBJECTIVE

To provide reference for improving the classification management of prescription drugs and nonprescriptiondrugs in China by learning from the classification management system of prescription drugs and non-prescription drugs in Canada.

METHODS

The content and experience of classification management system of prescription drugs and non-prescription drugs in Canada were analyzed， and the thinking of the classification management of prescription drugs and non-prescription drugs in China was proposed.

RESULTS & CONCLUSIONS

According to the classification of prescription drugs and non-prescription drugs， drugs can be divided into class Ⅰ drugs， class Ⅱ drugs， class Ⅲ drugs， unclassified drugs in Canada. Specific evaluation factors and management requirements have been established for drug classification. Canada has established a set of systematic management systems and technical standards， which has reference value for improving the classification management system in China. It is suggested to further improve the drug classification management system and supporting policies， strengthen fine classification management of prescription drugs and non-prescription drugs and improve classification registration and transformation review standards in China， by learning from Canadian prescription drug and non-prescription drug system and management model.

关键词

Keywords

references

朱兰，邵波，夏东胜 . 我国遴选与转换中成药非处方药概况及思考 [J ] . 中国药物警戒， 2020 ， 17 （ 11 ）： 785 - 789 .

Health Canada . Natural and non-prescription health pro- ducts directorate [EB/OL ] . （ 2020-03-05 ）[ 2022-07-12 ] . https：//www.canada.ca/en/health-canada/corporate/about-health-canada/branches-agencies/health-products-food-branch/natural-non-prescription-health-products-directo-rate.html https://www.canada.ca/en/health-canada/corporate/about-health-canada/branches-agencies/health-products-food-branch/natural-non-prescription-health-products-directo-rate.html .

NAPRA . Drug scheduling in Canada：general overview [EB/OL ] . （ 2022-07-06 ）[ 2022-07-12 ] . https：//www.napra.ca/drug-scheduling-canada-general-overview https://www.napra.ca/drug-scheduling-canada-general-overview .

Health Canada . Classification of products under the Food and Drugs Act （F&DA） [EB/OL ] . （ 2022-03-29 ）[ 2022-07-12 ] . https：//www.canada.ca/en/health-canada/services/drugs-health-products/classification-products-food-drug-sact.html https://www.canada.ca/en/health-canada/services/drugs-health-products/classification-products-food-drug-sact.html .

Laws Justice . Food and drug act [EB/OL ] . （ 2021-05-06 ）[ 2022-07-12 ] . https：//laws.justice.gc.ca/eng/acts/f-27/index.html https://laws.justice.gc.ca/eng/acts/f-27/index.html .

Health Canada . Regulation of non-prescription drugs [EB/OL ] . [ 2022-03-22 ] . https：//www.canada.ca/en/health-canada/services/self-care-regulation-non-prescription-drugs.html https://www.canada.ca/en/health-canada/services/self-care-regulation-non-prescription-drugs.html .

LEELAVANICH D ， ADJIMATERA N ， BROESE VAN GROENOU L ， et al . Prescription and non-prescription drug classification systems across countries：lessons learned for Thailand [J ] . Risk Manag Healthc Policy ， 2020 ， 13 ： 2753 - 2768 .

世界各国的保健食品监管 [EB/OL ] . （ 2017-08-22 ）[ 2022-07-06 ] . http：//chinawto.mofcom.gov.cn/article/jsbl/zszc/201708/20170802631073.shtml http://chinawto.mofcom.gov.cn/article/jsbl/zszc/201708/20170802631073.shtml .

Health Canada . About natural health products [EB/OL ] . [ 2022-03-14 ] . https：//www.canada.ca/en/health-canada/services/drugs-health-products/natural-non-prescription/regulation/about-products.html#a6 https://www.canada.ca/en/health-canada/services/drugs-health-products/natural-non-prescription/regulation/about-products.html#a6 .

NAPRA . Background on update to NAPRA NHP policy [EB/OL ] . （ 2022-01-19 ）[ 2022-07-06 ] . https：//napra.ca/background-update-napra-nhp-policy https://napra.ca/background-update-napra-nhp-policy .

Laws Justice . Natural health products regulations [EB/OL ] .（ 2022-02-18 ） [ 2022-07-12 ] . https：//laws.justice.gc.ca/eng/regulations/sor-2003-196/index.html https://laws.justice.gc.ca/eng/regulations/sor-2003-196/index.html .

Health Canada . Switching a medicinal ingredient from prescription to non-prescription status draft guidance document [EB/OL ] . （ 2022-04-21 ）[ 2022-07-13 ] . https：//www.canada.ca/en/health-canada/programs/consultation-draft-revised-guidance-switching-medicinal-ingredient-prescription-non-prescription/contact-information-glos- sary.html https://www.canada.ca/en/health-canada/programs/consultation-draft-revised-guidance-switching-medicinal-ingredient-prescription-non-prescription/contact-information-glos-sary.html .

Health Canada . Non-prescription drugs：category Ⅳ monographs [EB/OL ] . （ 2016-01-26 ）[ 2022-07-13 ] . https：//www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/non-prescription-drugs-category-iv-monographs.html https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/non-prescription-drugs-category-iv-monographs.html .

NAPRA . Rules of procedure [EB/OL ] .（ 2009-01-29 ） [ 2022-07-13 ] . https：//www.napra.ca/sites/default/files/documents/NDSAC_Rules_of_Procedure.pdf https://www.napra.ca/sites/default/files/documents/NDSAC_Rules_of_Procedure.pdf .

NAPRA . Application for drug scheduling [EB/OL ] . （ 2022-07-06 ）[ 2022-07-13 ] . https：//www.napra.ca/application-drug-scheduling https://www.napra.ca/application-drug-scheduling .

NAPRA . National drug scheduling factors [EB/OL ] . （ 2017-09-26 ）[ 2022-07-13 ] . https：//www.napra.ca/sites/default/files/documents/NDSAC_Scheduling_Factors_ website_September2017.pdf https://www.napra.ca/sites/default/files/documents/NDSAC_Scheduling_Factors_website_September2017.pdf .

NAPRA . Supplemental standards of practice Ⅱ and Ⅲ [EB/OL ] . （ 2005-8-12 ）[ 2022-07-13 ] . https：//www.napra.ca/sites/default/files/documents/SupplementalStandardsof- Practice https://www.napra.ca/sites/default/files/documents/SupplementalStandardsof-Practice ⅡandⅢ-June 2005 . pdf .

NAPRA . NDS Process and scheduling factors [EB/OL ] . （ 2022-07-06 ）[ 2022-07-13 ] . https：//www.napra.ca/nds-process-and-scheduling-factors https://www.napra.ca/nds-process-and-scheduling-factors .

NAPRA . Conditions of sale for each drug schedule [EB/OL ] . （ 2009-01-30 ）[ 2022-07-13 ] . https：//www.napra.ca/sites/default/files/documents/Schedules-Outline.pdf https://www.napra.ca/sites/default/files/documents/Schedules-Outline.pdf .

Views

350

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical value assessment of innovative drugs in Canada’s health insurance access

Related Author

JIANG Rong

SHENG Tianyi

SHAO Rong

Related Institution

The Research Center of National Drug Policy & Ecosystem， China Pharmaceutical University

NMPA Key Laboratory for Drug Regulatory Innovation and Evaluation

⁰